Business Daily Media

Men's Weekly

.

SABRE topline results: Cu-64 SAR-Bombesin is effective in detecting prostate cancer recurrence in patients with negative SOC imaging

  • Written by PR Newswire
SABRE topline results: Cu-64 SAR-Bombesin is effective in detecting prostate cancer recurrence in patients with negative SOC imaging

Highlights

  • Topline data from Clarity's diagnostic Phase II trial, SABRE, showed that 64Cu-SAR-Bombesin was safe, well tolerated and effective at detecting prostate cancer in patients with biochemical recurrence (BCR) who are negative or equivocal on standard-of-care (SOC) scans, including prostate-specific membrane antigen (PSMA) Positron...

Work-life Balance Key to Solving Construction Talent Shortage

New data from leading talent company Randstad Australia shows flexible working and work-life balance could be critical to addressing ongoing talen...

How to Apply for More Jobs in Less Time Using AI Automation

Most job seekers spend 11 to 14 hours per week on applications and still hear nothing back. That's not a motivation problem. That's a process proble...

Why Middle Australia Is Quietly Driving the Shift Away From Car Ownership

The narrative around changing attitudes to car ownership has long focused on Gen Z. Younger Australians are often portrayed as the generation movi...

Launchd Acquires WeAreTENZING as ANZ Creator Economy Spend Nears $1 Billion

Launchd, Australia's leading talent-first creator economy group, has acquired WeAreTENZING, one of New Zealand's most respected talent agencies, b...

Time to punch above our weight and stop shadowboxing on AI

Australia prides itself on being an innovation economy. We celebrate startups, talk about productivity, and lean into our reputation for punching ...

Colter Bay Capital Launches as Australia’s Newest Institutional Private Credit Fund

Led by seasoned capital markets veteran Mark Wang, the fund is purpose-built to serve Australia’s most productive yet chronically underserved busi...